Gastrointestinal Cancer

Step Count May Boost QOL in Patients Receiving SM-88

January 18, 2021

Mean daily step count during the first 2 weeks of treatment with SM-88 (racemetyrosine) was found to correlate with overall self-reported quality of life (QoL) in patients with metastatic pancreatic cancer.

FDA Approves Fam-Trastuzumab Deruxtecan-nxki for HER2+ Gastric Adenocarcinomas

January 16, 2021

The FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of patients with locally advanced or metastatic HER2-postive gastric or gastroesophageal (GEJ) adenocarcinoma who previously received a trastuzumab-based regimen.

Team Up, Be Aggressive: Improving Outcomes for Metastatic Colon Cancer

January 14, 2021

The management of patients with colorectal liver metastases is complicated and requires careful assessment from a multidisciplinary tumor board—especially in light of recent advances made with chemotherapy, according to Michael J. Cavnar, MD.

FDA Gives Priority Review to Frontline Pembrolizumab/Chemo for Esophageal/GEJ Cancer Subset

December 18, 2020

The FDA has granted priority review to a new supplemental biologics license application for pembrolizumab in combination with platinum- and fluoropyrimidine-based chemotherapy as a first-line treatment in patients with locally advanced unresectable or metastatic esophageal and gastroesophageal junction cancer.

Personalized Treatment Is Paramount in Colorectal Cancer

November 17, 2020

Colorectal cancer (CRC) treatment has entered an era that is both exciting and challenging, according to Nilofer S. Azad, MD, who emphasized that as new strategies continue to be explored, treatment decisions should be informed by tumor location, the alterations present, and tolerability.

Priority Review Granted to Trastuzumab Deruxtecan for HER2+ Metastatic Gastric Cancer

October 29, 2020

The FDA has accepted and granted a priority review designation to a supplemental biologics license application for the antibody-drug conjugate (ADC) trastuzumab deruxtecan (Enhertu) for use in patients with HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.